Drug Target Review

JUNE 6, 2025

At the forefront of this transformation is Dr Ebrahim Delpassand, a nuclear medicine physician and the driving force behind RadioMedix (RMX), a radiopharmaceutical company focused on developing targeted diagnostics and therapies. Why targeted radiopharmaceuticals? The SPICA Center was built to address this gap.”

Therapies

The Pharma Data

JUNE 18, 2025

The investigational ADC is built using Daiichi Sankyo’s proprietary DXd technology and represents one of the newest generation of targeted cancer therapies. Building on Early Clinical Success The Phase 3 IDeate-Prostate01 trial is based on encouraging results from the earlier IDeate-PanTumor01 Phase 1/2 study.

Trials

The Pharma Data

JUNE 16, 2025

a principal investigator for the TRANSCEND FL study and a lymphoma and cell therapy specialist at Memorial Sloan Kettering Cancer Center in New York. This high durability highlights the sustained Benefit provided by liso-cel in a population typically faced with poor prognosis after multiple lines of standard therapy. months, and 24.5

Therapies

The Pharma Data

JUNE 13, 2025

The data were presented during the 2025 European Hematology Association (EHA) Congress (Abstract #S239). Standard single-target CD19-directed CAR T-cell therapies typically enable long-term remissions in roughly 40% of patients, emphasizing a significant unmet need for new and more effective treatment strategies.

Therapies

The Pharma Data

JUNE 26, 2025

FDA Approves Streamlined Monitoring Requirements and REMS Program Removal for Bristol Myers Squibb’s CAR T Cell Therapies Breyanzi and Abecma, Marking Milestone Toward Expanding Access to Cancer Treatment In a significant regulatory development, Bristol Myers Squibb announced that the U.S.

FDA Approval

Drug Target Review

JULY 30, 2025

Radioligand therapy (RLT) has emerged as a powerful modality in oncology, offering highly targeted delivery of radiation to cancer cells while sparing healthy tissues. While Molecular Partners are the leaders in the development of DARPins, Orano Med is the leader in 212Pb-based radioligand therapy (RLT),” Julien explained. “By

Clinical Trials

Conversations in Drug Development Trends

NOVEMBER 12, 2024

By Amy Raymond, PhD, PMP, Executive Director, Therapeutic Strategy Lead, Rare Disease Cell and gene therapies (CGTs) include cutting-edge approaches that offer the hope of a healthier, happier, and better tomorrow for a wide range of patient populations. Operationalizing these trials requires proactive and flawless management at every stage.

Therapies

Drug Target Review

JULY 8, 2025

Not only are they chasing new targets, they are also working to understand the biology behind resistance, discover biomarkers that matter and build smarter therapies from the ground up. While there are already therapies under investigation that focus on PSMA alone, none are concurrently targeting STEAP1.

Therapies

The Pharma Data

JUNE 27, 2025

The trial met both its primary and key secondary endpoints, signaling a potential breakthrough in a condition with few, if any, effective treatment options. The trial met both its primary and key secondary endpoints, signaling a potential breakthrough in a condition with few, if any, effective treatment options.

Trials

Drug Target Review

JULY 24, 2025

Antibody therapies have transformed cancer treatment, yet their limits are becoming increasingly clear – particularly when tumours evolve, evade immune detection or develop resistance to existing drugs. For Dr Jhong-Jhe ‘JJ’ You, Vice President of Antibody Discovery at AP Biosciences, these challenges are not setbacks.

Immune Response

Drug Target Review

JUNE 11, 2025

Drug development faces significant challenges: long timelines, high costs , complex processes and low probabilities of success (PoS), exacerbated by the shift towards more complex molecules, biologics and cell and gene therapies, hindering patient access to vital treatments. Highlighting data integration. This is an AI generated image.

Drugs

The Pharma Data

JUNE 6, 2025

Otsuka Unveils Promising Phase 3 Results for Sibeprenlimab in IgA Nephropathy, Marking Significant Proteinuria Reduction and Advancing a Novel APRIL-Targeted Therapy Otsuka Pharmaceutical Development & Commercialization, Inc., in those receiving placebo—further underscoring the tolerability of this investigational therapy.

Trials

The Pharma Data

JUNE 23, 2025

These pivotal findings were unveiled at the 85th Scientific Sessions of the American Diabetes Association (ADA) and were concurrently published in The New England Journal of Medicine , underscoring the significant promise of MariTide in the growing field of anti-obesity therapies.

Trials

Drug Target Review

DECEMBER 23, 2024

While these therapies hold great promise for improving cancer treatment outcomes, their development presents significant challenges, especially in achieving the optimal balance between efficacy and safety. It also enables a more targeted approach to ADC optimisation, minimising the need for trial-and-error experimentation.

Research

SugarCone Biotech

JUNE 19, 2025

They have interesting patterns of expression in different cancer indications; thus, diverse therapies for attacking these targets have been developed. SCLC generally has a “hot” tumor microenvironment (TME) meaning that it is infiltrated by immune cells, including the T cells that are activated by immune checkpoint therapies.

Therapies

The Pharma Data

JUNE 22, 2025

In the trial, participants were directly switched to Mim8 without a washout period. Strong Safety Profile Reinforces Mim8’s Potential Mim8’s safety profile was a central focus of the FRONTIER5 trial. Throughout the 26-week study period, the investigational therapy was well-tolerated.

Pharmacokinetics

The Pharma Data

JUNE 26, 2025

Held at a pivotal juncture for the company, the R&D Day offered an opportunity for BeOne’s executive and scientific leaders to present new clinical data, pipeline milestones, and strategic insights that reaffirm its mission: to build the world’s first next-generation oncology company.

Research

PPD

MARCH 11, 2025

Breaking through research barriers Challenge #1: Small groups of patients Rare diseases impact a small number of individuals, making it difficult to recruit enough participants for clinical trials. Moreover, in some rare disease trials, it is unethical to design a control group of patients with a placebo.

Drug Development

The Pharma Data

JUNE 22, 2025

The results from the Phase I/II NXTAGE trial, announced during the 2025 International Society on Thrombosis and Haemostasis (ISTH) Congress in Washington, D.C., The results from the Phase I/II NXTAGE trial, announced during the 2025 International Society on Thrombosis and Haemostasis (ISTH) Congress in Washington, D.C.,

Clinical Trials

The Pharma Data

JUNE 12, 2025

The data were revealed during an oral presentation (S137) at the 2025 European Hematology Association (EHA) Congress in Vienna, reflecting ongoing progress in developing new treatment options for patients battling this aggressive hematologic malignancy.

Treatment

The Pharma Data

JUNE 9, 2025

The data were featured as part of four oral presentations selected by the Associated Professional Sleep Societies (APSS) for their scientific innovation and clinical relevance, with Jazz accounting for all the industry-sponsored late-breaking oral presentations at the meeting. According to Dr. Richard J.

FDA Approval

PPD

DECEMBER 16, 2024

Cost and complexity go hand-in-hand The rising costs and growing complexity in clinical trials are deeply linked, with patient recruitment, extended timelines and meeting regulatory demands emerging as some of the key drivers. Nearly half (49%) of clinical trial sponsors surveyed identified rising costs as their foremost concern in 2024.

Drug Development

Drug Target Review

JUNE 28, 2025

DARPin therapeutics were a prominent theme at AACR 2025 , with Molecular Partners presenting a trio of preclinical programmes spanning radiopharmaceuticals and immune cell engagers. “My passion for science drew me to DARPin technology, and I was eager to contribute to the development of new DARPin therapies.”

Science

Drug Target Review

JULY 18, 2025

Tackling resistance from a different angle: PAR2 While CCR8 is drawing attention, Domain is also exploring less conventional GPCRs like PAR2 – long known in inflammation and pain, but only recently linked to cancer therapy resistance. Presenting our data at the AACR was an incredibly rewarding experience,” says Schann.

Medical Chemistry

The Pharma Data

AUGUST 1, 2025

This regulatory privilege is reserved for investigational therapies that demonstrate the potential to offer a major therapeutic advantage over existing treatments or benefit patients without treatment options. The disease commonly presents with fatigue, anemia, peripheral neuropathy, and complications related to hyperviscosity of the blood.

Targeted Protein Degradation

The Pharma Data

AUGUST 1, 2025

Drugs that appear effective and safe in preclinical studies often fail in human trials, leading to costly setbacks, prolonged timelines, and significant patient risk. Ethical Impact: Supporting the 3Rs in Drug Discovery Beyond technological innovation, the Altasciences-VoxCell partnership carries a significant ethical dimension.

Drug Development

The Pharma Data

JUNE 6, 2025

The data underscored the significant clinical benefits associated with cystic fibrosis transmembrane conductance regulator (CFTR) modulators—particularly its next-generation triple therapy, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor).

Therapies

The Pharma Data

JUNE 12, 2025

Foundation, explained during the EULAR 2025 presentation: “IgG4-related disease is a progressive, immune-mediated condition with a significant unmet patient need. Importantly, most participants presented with active disease in at least one organ , with the exception of the lymph nodes.

Disease

New Drug Approvals

JULY 9, 2025

5] In China, it was conditionally approved in 2023 for the treatment of NSCLC and full approval is contingent on results of phase 3 clinical trials. [6] 7] Efficacy was evaluated in WU-KONG1B (NCT03974022), a multinational, open-label, dose randomization trial. [1] 1] History Sunvozertinib is being developed by Dizal Pharmaceutical. [5]

FDA

The Pharma Data

AUGUST 3, 2025

The five-year results were derived from the Phase III Portal study, a long-term extension of the pivotal Archway trial, and presented at the American Society of Retina Specialists (ASRS) 2025 Annual Meeting held in Long Beach, California. Susvimo was designed to directly address this issue.

Treatment

Drug Target Review

DECEMBER 16, 2024

In addition to this, I also chaired national trials evaluating an anti-GD2 antibody in pediatric osteosarcoma. Being a woman and an immigrant presented challenges in my professional growth along the way. Throughout her academic career, she worked in translational and clinical research, focusing on novel therapies for pediatric cancers.

Medical Schools

The Pharma Data

JUNE 6, 2025

At this premier global meeting focused on thrombosis, hemostasis, and bleeding disorders, Sanofi will present compelling data across 18 scientific abstracts, including five oral presentations. In addition, two poster presentations will offer deeper insights into the LUNA 3 trial. In the U.S.,

Disease

The Pharma Data

JUNE 15, 2025

today presented new and significant data demonstrating the superiority of Dupixent® (dupilumab) over Xolair® (omalizumab) in a first-of-its-kind, head-to-head, Phase 4 study in adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP) and co-existing asthma.

Treatment

The Pharma Data

JUNE 11, 2025

argenx Unveils Positive Phase 2 Results for Efgartigimod in Myositis and Sjogren’s Disease at EULAR 2025 argenx SE a global immunology company dedicated to advancing treatments for severe autoimmune diseases, presented encouraging new clinical data at the 2025 European Congress of Rheumatology (EULAR), held June 11–14 in Barcelona, Spain.

Disease

The Pharma Data

JUNE 15, 2025

The data, which encompass up to 3 years of follow-up after a single infusion of the treatment, were shared in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, held from June 13–16 in Glasgow, United Kingdom. President and Chief Executive Officer of Intellia Therapeutics.

Treatment

Drug Patent Watch

DECEMBER 9, 2024

This includes: Preclinical studies Clinical trials Regulatory approval Manufacturing and marketing Throughout this process, pharmaceutical companies seek to protect their investments through patents. It’s a delicate balance between incentivizing research and ensuring equitable access to medicines.”

Drugs

The Pharma Data

JUNE 18, 2025

The presentations will also include new insights from Amgen’s Phase 3 FOURIER study of Repatha® (evolocumab) and the VESALIUS-REAL study exploring real-world lipid management practices. These new 52-week data will be unveiled during a dedicated symposium scheduled for Monday, June 23, from 1:30 p.m. to 3:00 p.m.

Therapies